KURA ONCOLOGY, INC. Investment Income, Interest
KURA ONCOLOGY, INC. (KURA) reported Investment Income, Interest of $450.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2018-05-08
- KURA ONCOLOGY, INC. investment income, interest for the quarter ending 2018-03-31 was $450.00K, a 251.56% increase year-over-year.
- KURA ONCOLOGY, INC. investment income, interest for the quarter ending 2017-12-31 was $302.00K, a 132.31% increase year-over-year.
- KURA ONCOLOGY, INC. investment income, interest for the quarter ending 2017-09-30 was $197.00K, a 50.38% increase year-over-year.
- KURA ONCOLOGY, INC. investment income, interest for the quarter ending 2017-06-30 was $124.00K, a 0.00% change year-over-year.
- KURA ONCOLOGY, INC. investment income, interest for fiscal 2017 was $751.00K, a 50.50% increase from fiscal 2016.
- KURA ONCOLOGY, INC. investment income, interest for fiscal 2016 was $499.00K, a 289.84% increase from fiscal 2015.
- KURA ONCOLOGY, INC. investment income, interest for fiscal 2015 was $128.00K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2018-03-31 | $450.00K 10-Q · filed 2018-05-08 | $752.00K derived: sum of 2 quarters · filed 2018-05-08 | $949.00K derived: sum of 3 quarters · filed 2018-05-08 | $1.07M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $499.00K derived: sum of 2 quarters · filed 2018-03-12 | $623.00K derived: sum of 3 quarters · filed 2018-03-12 | $751.00K 10-K · filed 2018-03-12 |
| 2017-09-30 | $197.00K 10-Q · filed 2017-11-07 | $321.00K derived: sum of 2 quarters · filed 2017-11-07 | $449.00K 10-Q · filed 2017-11-07 | $579.00K derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | $124.00K 10-Q · filed 2017-08-07 | $252.00K 10-Q · filed 2017-08-07 | $382.00K derived: sum of 3 quarters · filed 2018-05-08 | $513.00K derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | $128.00K 10-Q · filed 2018-05-08 | $258.00K derived: sum of 2 quarters · filed 2018-05-08 | $389.00K derived: sum of 3 quarters · filed 2018-05-08 | $513.00K derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $261.00K derived: sum of 2 quarters · filed 2018-03-12 | $385.00K derived: sum of 3 quarters · filed 2018-03-12 | $499.00K 10-K · filed 2018-03-12 |
| 2016-09-30 | $131.00K 10-Q · filed 2017-11-07 | $255.00K derived: sum of 2 quarters · filed 2017-11-07 | $369.00K 10-Q · filed 2017-11-07 | $437.00K derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-06-30 | $124.00K 10-Q · filed 2017-08-07 | $238.00K 10-Q · filed 2017-08-07 | $306.00K derived: sum of 3 quarters · filed 2017-08-07 | $344.00K derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-03-31 | $114.00K 10-Q · filed 2017-05-15 | $182.00K derived: sum of 2 quarters · filed 2017-05-15 | $220.00K derived: sum of 3 quarters · filed 2017-05-15 | $242.00K derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $106.00K derived: sum of 2 quarters · filed 2017-03-14 | $128.00K derived: sum of 3 quarters · filed 2017-03-14 | $128.00K 10-K · filed 2017-03-14 |
| 2015-09-30 | $38.00K 10-Q · filed 2016-11-07 | $60.00K derived: sum of 2 quarters · filed 2016-11-07 | $60.00K 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $22.00K 10-Q · filed 2016-08-10 | $22.00K 10-Q · filed 2016-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |